| Identification | Back Directory | [Name]
FX-11 | [CAS]
213971-34-7 | [Synonyms]
FX-11
LDHA Inhibitor FX11
FX-11
(LDHA inhibitor FX11)
7-benzyl-2,3-dihydroxy-6-methyl-4-propylnaphthalene-1-carboxylic acid
2,3-Dihydroxy-6-Methyl-7-(phenylMethyl)-4-propyl-1-naphthalenecarboxylic Acid
1-Naphthalenecarboxylic acid, 2,3-dihydroxy-6-methyl-7-(phenylmethyl)-4-propyl- | [Molecular Formula]
C22H22O4 | [MOL File]
213971-34-7.mol | [Molecular Weight]
350.41 |
| Chemical Properties | Back Directory | [Melting point ]
183-184 °C | [Boiling point ]
570.1±50.0 °C(Predicted) | [density ]
1.260±0.06 g/cm3(Predicted) | [storage temp. ]
-20°C Freezer, Under inert atmosphere | [solubility ]
DMSO (Slightly), Methanol (Slightly) | [form ]
Solid | [pka]
3.70±0.40(Predicted) | [color ]
Light Grey to Light Brown | [InChI]
InChI=1S/C22H22O4/c1-3-7-16-17-10-13(2)15(11-14-8-5-4-6-9-14)12-18(17)19(22(25)26)21(24)20(16)23/h4-6,8-10,12,23-24H,3,7,11H2,1-2H3,(H,25,26) | [InChIKey]
LVPYVYFMCKYFCZ-UHFFFAOYSA-N | [SMILES]
C1(C(O)=O)=C2C(C=C(C)C(CC3=CC=CC=C3)=C2)=C(CCC)C(O)=C1O |
| Hazard Information | Back Directory | [Description]
FX-11 is an inhibitor of lactate dehydrogenase-A (LDH-A; Ki = 8 μM). It is selective for LDH-A over GAPDH (Ki = >300 μM). FX-11 increases oxygen consumption and the production of reactive oxygen species (ROS), as well as induces cell death in P493-6 lymphoblastoid cells. In vivo, FX-11 (42 μg/animal, i.p.) reduces tumor volume in a P493-6 mouse xenograft model. It also reduces tumor weight in a BxPC-3 mouse xenograft model when administered at a dose of 2 mg/kg.
| [Uses]
This compound is used in the synthesis of novel lactate dehydrogenase A inhibitors. | [in vivo]
FX-11 (42 μg/mouse; IP, daily for 10-14 days) inhibits P493 tumor growth[2].
FX-11 (0-2 mg/kg, IP, daily, for 3 weeks) significantly delays tumor growth[3]. | Animal Model: | Male SCID mice and RH-Foxn1nu mice (human P493 B-cell xenografts)[2] | | Dosage: | 42 μg/mouse (2.1 mg/kg) | | Administration: | IP; daily for 10-14 days | | Result: | Resulted in a remarkable inhibition of tumor growth, inhibited tumor xenograft progression. |
| Animal Model: | Immunocompromised CD-1 mice (6-8 weeks; 20-25 g, n=5 per group)[3] | | Dosage: | 2 mg/kg, 1 mg/kg+15 mg/kg TEPP-46, 2 mg/kg+30 mg/kg TEPP-46 | | Administration: | IP (100 μL), daily, for 3 weeks | | Result: | Significantly lowered LDHA activity in plasma and tumor lysates; significantly lowered the expression of the proliferation marker Ki-67; significantly decreased proliferation indices were observed in tumor sections; significantly delayed tumor growth. |
| [storage]
Store at -20°C | [References]
[1] ANNE LE. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression.[J]. Proceedings of the National Academy of Sciences of the United States of America, 2010: 2037-2042. DOI: 10.1073/pnas.0914433107
[2] G. MOHAMMAD. Targeting Pyruvate Kinase M2 and Lactate Dehydrogenase A Is an Effective Combination Strategy for the Treatment of Pancreatic Cancer[J]. Cancers, 2019. DOI: 10.3390/cancers11091372 |
|
|